Rod Humerickhouse

18.5k total citations · 6 hit papers
107 papers, 8.1k citations indexed

About

Rod Humerickhouse is a scholar working on Genetics, Oncology and Molecular Biology. According to data from OpenAlex, Rod Humerickhouse has authored 107 papers receiving a total of 8.1k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Genetics, 36 papers in Oncology and 34 papers in Molecular Biology. Recurrent topics in Rod Humerickhouse's work include Chronic Lymphocytic Leukemia Research (56 papers), Lymphoma Diagnosis and Treatment (24 papers) and Cancer Treatment and Pharmacology (16 papers). Rod Humerickhouse is often cited by papers focused on Chronic Lymphocytic Leukemia Research (56 papers), Lymphoma Diagnosis and Treatment (24 papers) and Cancer Treatment and Pharmacology (16 papers). Rod Humerickhouse collaborates with scholars based in United States, Australia and Germany. Rod Humerickhouse's co-authors include Sari H. Enschede, John F. Seymour, Thomas J. Kipps, William G. Wierda, Martin Dunbar, Andrew W. Roberts, Hao Xiong, John F. Gerecitano, Shekman Wong and Matthew S. Davids and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Rod Humerickhouse

106 papers receiving 8.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

2015 1.3k citations Andrew W. Roberts, Matthew S. Davids et al. New England Journal of Medicine profile →
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

2010 663 citations Wyndham H. Wilson, Owen A. O’Connor et al. The Lancet Oncology profile →
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

2011 632 citations Andrew W. Roberts, John F. Seymour et al. Journal of Clinical Oncology profile →
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia

2018 595 citations John F. Seymour, Thomas J. Kipps et al. New England Journal of Medicine profile →
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

2018 498 citations Courtney D. DiNardo, Anthony Letai et al. The Lancet Oncology profile →
Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study

2019 456 citations Andrew H. Wei, Stephen A. Strickland et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Rod Humerickhouse

Since Specialization

Citations

This map shows the geographic impact of Rod Humerickhouse's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rod Humerickhouse with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rod Humerickhouse more than expected).

Fields of papers citing papers by Rod Humerickhouse

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rod Humerickhouse. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rod Humerickhouse. The network helps show where Rod Humerickhouse may publish in the future.

Co-authorship network of co-authors of Rod Humerickhouse

This figure shows the co-authorship network connecting the top 25 collaborators of Rod Humerickhouse. A scholar is included among the top collaborators of Rod Humerickhouse based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rod Humerickhouse. Rod Humerickhouse is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A Phase 1 and Biodistribution Study of ABT-806i, an ¹¹¹In-Radiolabeled Conjugate of the Tumor-Specific Anti-EGFR Antibody ABT-806 2021 ·Journal of Nuclear Medicine ·Hui Gan, Matthew Burge, Benjamin Solomon, Sze Ting Lee, Kyle D. Holen, Yumin Zhang, Marika Ciprotti, (unknown), Wijith Munasinghe, (unknown), Peter Ansell, Gerard B. Fox, Hao Xiong, Edward B. Reilly, Rod Humerickhouse, Andrew M. Scott	15
2	Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study breakdown → 2019 ·Journal of Clinical Oncology ·Andrew H. Wei, Stephen A. Strickland, Jing-Zhou Hou, Walter Fiedler, Tara L. Lin, Roland B. Walter, Anoop Enjeti, Ing Soo Tiong, Michael R. Savona, Sang‐Min Lee, Brenda Chyla, Relja Popovic, Ahmed Hamed Salem, Suresh Agarwal, Tu Xu, Kaffa Fakouhi, Rod Humerickhouse, (unknown), John Hayslip, Gail J. Roboz	456
3	Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy 2019 ·Haematologica ·(unknown), William G. Wierda, Matthew S. Davids, Bruce D. Cheson, Steven Coutré, Michael Y. Choi, Richard R. Furman, Leonard T. Heffner, Paul M. Barr, Herbert Eradat, (unknown), Lang Zhou, Maria Verdugo, Rod Humerickhouse, Jalaja Potluri, John C. Byrd	28
4	Venetoclax (VEN) Is Active in Chronic Lymphocytic Leukemia (CLL) Relapsed or Refractory to More Than One B-Cell Receptor Pathway Inhibitor (BCRi) 2017 ·Blood ·William G. Wierda, Matthew S. Davids, Richard R. Furman, Bruce D. Cheson, Paul M. Barr, Herbert Eradat, Leonard T. Heffner, Jeffrey A. Jones, Lang Zhou, Maria Verdugo, Rod Humerickhouse, Jalaja Potluri, Michael Y. Choi	3
5	A Phase 1 and Biodistribution Study of Abt-806I, An Indium-111 Radiolabeled Conjugate of the Tumor-Specific Anti-Egfr Antibody Abt-806 2017 ·Internal Medicine Journal ·Hui Gan, Matthew Burge, Benjamin Solomon, (unknown), Kyle D. Holen, (unknown), Marika Ciprotti, (unknown), Thomas Merdan, Wijith Munasinghe, (unknown), Peter Ansell, Gerard B. Fox, Hao Xiong, (unknown), Rod Humerickhouse, Andrew M. Scott	2
6	Sustained Minimal Residual Disease Negativity Predicted in Chronic Lymphocytic Leukemia Patients Treated with Venetoclax Combination Therapy for 2 Years: an Integrated Mechanistic Analysis of Multiple Phase I and II Studies 2017 ·Blood ·Sathej Gopalakrishnan, Brenda Chyla, Sven Mensing, Rajeev Menon, Rod Humerickhouse, Walid M. Awni, Ahmed Hamed Salem, Kevin J. Freise	2
7	Venetoclax Plus Rituximab Is Superior to Bendamustine Plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano Study 2017 ·Blood ·John F. Seymour, Thomas J. Kipps, Barbara Eichhorst, Peter Hillmen, (unknown), Sarit Assouline, Carolyn Owen, John F. Gerecitano, Tadeusz Robak, Javier de la Serna, Ulrich Jaeger, Guillaume Cartron, Marco Montillo, Rod Humerickhouse, Elizabeth A. Punnoose, Yan Li, Michelle Boyer, Kathryn Humphrey, Mehrdad Mobasher, Arnon P. Kater	15
8	Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia 2016 ·Clinical Pharmacokinetics ·Kevin J. Freise, (unknown), (unknown), Sven Mensing, Shekman Wong, Rod Humerickhouse, Walid M. Awni, Ahmed Hamed Salem	52
9	Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia breakdown → 2015 ·New England Journal of Medicine ·Andrew W. Roberts, Matthew S. Davids, John M. Pagel, Brad S. Kahl, Soham D. Puvvada, John F. Gerecitano, Thomas J. Kipps, Mary Ann Anderson, Jennifer R. Brown, Lori A. Gressick, Shekman Wong, Martin Dunbar, Ming Zhu, Monali Desai, Elisa Cerri, Sari H. Enschede, Rod Humerickhouse, William G. Wierda, John F. Seymour	1337
10	A Phase 1 Study of Venetoclax (ABT-199 / GDC-0199) Monotherapy in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma 2015 ·Blood ·John F. Gerecitano, Andrew W. Roberts, John F. Seymour, William G. Wierda, Brad S. Kahl, John M. Pagel, Soham D. Puvvada, Thomas J. Kipps, Mary Ann Anderson, Martin Dunbar, Ming Zhu, Lori A. Gressick, (unknown), Su Young Kim, (unknown), Rod Humerickhouse, Matthew S. Davids	60
11	Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of navitoclax (ABT-263) induced thrombocytopenia 2014 ·Cancer Chemotherapy and Pharmacology ·(unknown), Jianning Yang, Peter Noertersheuser, Sven Mensing, Rod Humerickhouse, Walid M. Awni, Hao Xiong	118
12	A Phase 2 Study of ABT-199 (GDC-0199) in Patients with Acute Myelogenous Leukemia (AML) 2014 ·Blood ·Marina Konopleva, Daniel A. Pollyea, Jalaja Potluri, Brenda Chyla, Todd Busman, Evelyn McKeegan, Ahmed Hamed Salem, Ming Zhu, Justin L. Ricker, William Blum, Courtney D. DiNardo, Martin Dunbar, Rachel Kirby, Nancy Falotico, Joel Johansson, Rod Humerickhouse, Mack Mabry, Richard M. Stone, Hagop M. Kantarjian, Anthony Letai	50
13	The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study 2012 ·Blood ·John F. Seymour, Matthew S. Davids, Mary Ann Anderson, Thomas J. Kipps, William G. Wierda, John M. Pagel, Brad S. Kahl, Thomas P. Miller, (unknown), Cathy E. Nolan, Lori A. Gressick, Hao Xiong, David C.S. Huang, Brenda Chyla, Todd Busman, Alison M. Graham, Elisa Cerri, Sari H. Enschede, Rod Humerickhouse, Andrew W. Roberts	6
14	Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity breakdown → 2010 ·The Lancet Oncology ·Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman, Ann S. LaCasce, John F. Gerecitano, John P. Leonard, Anil Tulpule, Kieron Dunleavy, Hao Xiong, Yi‐Lin Chiu, Yue Cui, Todd Busman, Steven W. Elmore, Saul H. Rosenberg, Andrew Krivoshik, Sari H. Enschede, Rod Humerickhouse	663
15	Dynamic contrast enhanced MRI (DCE-MRI) for assessment of effects of anti-angiogenic therapy: Comparison of the transfer constant (Ktrans) to blood flow and permeability derived by a distributed parameter model 2007 ·Clinical Cancer Research ·Choon Hua Thng, Tong San Koh, Septian Hartono, Helmut Rumpel, James B. K. Khoo, Albert Low, (unknown), (unknown), Bee Choo Tai, Ross A. Soo, Rod Humerickhouse, Boon Cher Goh	1
16	Phase I study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 with 5-fluorouracil and leucovorin: A safe combination 2006 ·European Journal of Cancer ·Ronald Hoekstra, Filip De Vos, Ferry A.L.M. Eskens, Elisabeth G.E. de Vries, D. R. A. Uges, Raymond A. Knight, Robert Carr, Rod Humerickhouse, Jaap Verweij, Jourik A. Gietema	38
17	Characterization of human circulating endothelial cells to monitor response to antitumor therapy in human clinical trials 2006 ·Clinical Cancer Research ·Evelyn McKeegan, Dawn M. Carlson, Raymond A. Knight, Milagros Colon-Lopez, Peter J. DeVries, Rod Humerickhouse, Rick Lesniewski	1
18	Activation and deactivation of sarcoplasmic reticulum calcium release channels: Molecular dissection of mechanisms via novel semi-synthetic ryanoids 1995 ·Molecular and Cellular Biochemistry ·Keshore R. Bidasee, Henry R. Besch, Koert Gerzon, Rod Humerickhouse	9
19	Structural Determinants of High-Affinity Binding of Ryanoids to the Vertebrate Skeletal Muscle Ryanodine Receptor: A Comparative Molecular Field Analysis 1994 ·Biochemistry ·William H. Welch, Syed Sayeed Ahmad, Judith A. Airey, Koert Gerzon, Rod Humerickhouse, (unknown), Luc Ruest, Pierre Deslongchamps, John L. Sutko	37
20	Differential activating and deactivating effects of natural ryanodine congeners on the calcium release channel of sarcoplasmic reticulum: evidence for separation of effects at functionally distinct sites. 1993 ·Molecular Pharmacology ·Rod Humerickhouse, Henry R. Besch, Koert Gerzon, Luc Ruest, John L. Sutko, Jeffrey T. Emmick	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact